A Phase II Evaluation of Trabectedin (Yondelis, R279741) in the Treatment of Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Trabectedin (Primary)
- Indications Leiomyosarcoma
- Focus Adverse reactions; Therapeutic Use
- 14 Aug 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
- 03 Mar 2010 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center, Northwestern University record no. GOG0087M).
- 04 Nov 2008 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.